Strong beat on both revenue and EPS, coupled with record YCANTH demand and pipeline milestones, reinforces positive momentum. Monitor upcoming SID VP-315 data (May 13-16) and Phase 3 common warts enrollment updates for further catalysts.
Price Chart
Executive Summary
Verrica Pharmaceuticals reported Q1 2026 revenue of $5.0M (beat consensus of $4.5M by 11.6%) and GAAP EPS of -$0.45 (beat consensus of -$0.59 by 23.7%). YCANTH dispensed units hit a record 15,302, up 51% YoY, and the Japan launch by Torii marks expansion into the first ex-U.S. market. Pipeline progress includes >50% enrollment in the Phase 3 common warts trial and upcoming VP-315 data at SID.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $5.0M, up 46% YoY from $3.4M
- GAAP EPS -$0.45 vs consensus -$0.59, beat by 23.7%
- YCANTH net product revenue $4.3M, up 25% YoY
- Dispensed applicator units record 15,302 in Q1, up 51% YoY
- Cash balance $20.6M as of March 31, 2026
- Japan launch of YCANTH by partner Torii in February 2026
- Over 50% enrolled in first Phase 3 common warts trial (COVE-2); second trial expected mid-2026
Financial Impact
Revenue beat by $0.5M (11.6%) and EPS beat by $0.14 (23.7%) vs consensus; YCANTH revenue growth accelerating.
Risk Factors
- Continued net loss of $9.7M per quarter; cash burn may require future financing
- Dependence on YCANTH adoption and insurance coverage
- Clinical and regulatory risks for common warts and VP-315 programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293348 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Press Release | $4.95 $4.18 | ▼ −15.56% | ▼ −17.68% | $3.47 (−29.90%) |
Jun 9, 2026 19w ago | 8-K | $5.75 $6.53 | ▲ +13.57% | ▲ +9.94% | $3.47 (−39.65%) |
May 12, 2026 23w ago | 8-K | $7.37 $6.03 | ▼ −18.25% | ▼ −17.64% | $3.47 (−52.92%) |
May 12, 2026 24w ago | Press Release | $7.37 $6.03 | ▼ −18.25% | ▼ −17.64% | $3.47 (−52.92%) |
Apr 20, 2026 27w ago | DEFA14A | $6.32 $5.87 | ▼ −7.12% | ▼ −12.04% | $3.47 (−45.09%) |
Mar 11, 2026 32w ago | Press Release | $6.26 $5.83 | ▼ −6.87% | ▼ −7.39% | $3.47 (−44.57%) |
Mar 4, 2026 33w ago | Court Ruling | $5.20 $5.47 | ▼ −5.19% | ▼ −8.67% | $3.47 (+33.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers